APO866

DRUG3 trials

Sponsors

Valerio Therapeutics

Conditions

B-cell Chronic Lymphocytic LeukemiaCutaneous T-cell LymphomaMelanoma

Phase 1

A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLL

CompletedNCT00435084

Valerio TherapeuticsB-cell Chronic Lymphocytic Leukemia

Start: 2007-02-28End: 2009-04-30Updated: 2015-09-23

Phase 2

A Study of APO866 for the Treatment of Cutaneous T-cell Lymphoma

CompletedNCT00431912

Valerio TherapeuticsCutaneous T-cell Lymphoma

Start: 2007-02-28End: 2011-09-30Updated: 2015-07-08

A Study to Assess APO866 for the Treatment of Advanced Melanoma

CompletedNCT00432107

Valerio TherapeuticsMelanoma

Start: 2006-07-31End: 2009-03-31Updated: 2015-09-29

Related Papers

A multicenter, open label, phase II study to assess the efficacy and safety of APO866 in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma.

Journal of Clinical Oncology2015-05-201 citations